Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 3

07:51 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 51–75 of 7,900+

Probably Relevant

Pain Therapeutics Will Make the Case for an FDA Reversal on Remoxy

Texas-based Pain Therapeutics is urging the FDA to reconsider the Complete Response Letter it issued in August for the company’s opioid-treatment, Remoxy. Representatives from Pain Therapeutics will meet with the FDA on Jan. 31. 2019 to discuss the request, the company announced late Monday.


Evox Therapeutics raises new funds to support drug development

UK-based therapeutics developer Evox Therapeutics has secured $45.4m in a series B financing round to support new drug development. The...Read More... The post Evox Therapeutics raises new funds to support drug development appeared first on Pharmaceutical Technology.

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.


The Current issue of “The view from here” is concerned with Therapeutics

The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”

In The Spotlight: PTC Therapeutics

Shares of PTC Therapeutics Inc. (PTCT) have gained as much as 24% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) is up just 8.6% for the same period.

Lilly's Olumiant Makes Big Leap In Lupus Trial

A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis...   

Rubius Therapeutics brings in new CEO

Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company. Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March. read more

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan Legault told INN. The post Antibe Therapeutics Looking for More Licensing Deals appeared first on Investing News Network.

Transition Therapeutics licenses drug candidate from Eli Lilly

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...

Apricus Biosciences Announces Merger Agreement with Seelos Therapeutics

Apricus Biosciences (NASDAQ:APRI) has announced it has signed an agreement to merge with Seelos Therapeutics in an all-stock transaction. As quoted in the press release: The merged company will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need. Upon … Continued The post Apricus...

Roche To Use Lodo Therapeutics' Drug Discovery Platform

NewsUnder the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.

Silence Therapeutics chief executive Mortazavi steps down

RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay. Silence said that unti...

Refocused Moderna Therapeutics barrels toward historic IPO

Since its launch in 2010, Moderna Therapeutics has become as famous for its valuation as it has for the secrecy...Read More... The post Refocused Moderna Therapeutics barrels toward historic IPO appeared first on Pharmaceutical Technology.

Genentech, Lodo Therapeutics form $969m drug discovery collaboration

Roche’s subsidiary Genentech has entered into a strategic drug discovery collaboration with Lodo Therapeutics, which is focused on the creation of therapeutics derived from nature that will impact patients across the world.

Appointments: Gilead, Shield Therapeutics, Gelesis, TG Therapeutics, Aziyo Biologics, Allogene Therapeutics, Mesoblast and CGT Catapult Make New Hires

Latest appointments announced by pharma and biotech firms.      

Oncology startup TP Therapeutics raises $80m in financing

New investors HBM Healthcare Investments (Cayman) and Nextech Invest also took part in the mezzanine financing, said TP Therapeutics. The new capital secured by the clinical-stage precision oncology The post Oncology startup TP Therapeutics raises $80m in financing appeared first on Pharma Business review.

TapImmune agrees to merge with Marker Therapeutics

US-based immunotherapies company TapImmune has signed a definitive merger agreement to buy multi-antigen T-cell therapy platform developer Marker Therapeutics. The...Read More... The post TapImmune agrees to merge with Marker Therapeutics appeared first on Pharmaceutical Technology.

Cybrexa Therapeutics to Present Preclinical Data for its Tumor-Selective Technology Platform at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology platform, today announced that the company will present preclinical data at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium to be held November 13 - 16, 2018 in Dublin, Ireland. The prec...

Amicus Therapeutics and Penn partner on new AAV gene therapies

US-based biotechnology firm Amicus Therapeutics has entered into a research, collaboration and licence agreement with the Perelman School of Medicine...Read More... The post Amicus Therapeutics and Penn partner on new AAV gene therapies appeared first on Pharmaceutical Technology.

Biotechnology firm Stoke Therapeutics raises $90m financing

The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic The post Biotechnology firm Stoke Therapeutics raises $90m financing appeared first on Pharma Business review.

Magenta’s Bastiano Sanna Appointed Semma Therapeutics CEO

Bastiano Sanna has been named CEO and president of Semma Therapeutics. Elizabeth Stoner, who has been serving as interim CEO, will remain as an advisor to the company. Sanna comes to Cambridge, MA-based Senna from Magenta Therapeutics, where he was chief operating officer. His experience also includes positions at Novartis (NYSE: NVS). Semma is developing […]

TP Therapeutics, Almac to develop NGS companion diagnostic for repotrectinib

The repotrectinib investigational therapy of TP Therapeutics is designed to target ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors. As per the terms of the agreement, The post TP Therapeutics, Almac to develop NGS companion diagnostic for repotrectinib appeared first on Compelo Medical Devices.

Deals this week: Kazia Therapeutics, Zymeworks, CANbridge

Kazia Therapeutics has signed a collaboration agreement with Dana-Farber Cancer Institute to trial GDC-0084 for the treatment of patients diagnosed...Read More... The post Deals this week: Kazia Therapeutics, Zymeworks, CANbridge appeared first on Drug Development Technology.

TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push

Five-year-old biotech TP Therapeutics has raised an $80 million mezzanine financing round and promoted its chief medical officer, Athena Countouriotis, to CEO. The San Diego-based biotech, which is developing targeted cancer drugs for people whose tumors resist other precision therapies, announced the changes Friday. TP Therapeutics is developing a drug called repotrectinib that targets a […...

Vectalys, Flashcell Merge to Form New Gene Therapy Company

Flash Therapeutics to develop RNA-based therapeutics and provide broad lentiviral development and manufacturing services


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks